(Q40751042)

23 September 2017

title

Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan (English)

1 reference

23 September 2017

Junji Tsurutani

1

1 reference

23 September 2017

Takashi Nitta

2

1 reference

23 September 2017

Tomonori Hirashima

3

1 reference

23 September 2017

Takefumi Komiya

4

1 reference

23 September 2017

Hisao Uejima

5

1 reference

23 September 2017

Hirohito Tada

6

1 reference

23 September 2017

Negoro Syunichi

7

1 reference

23 September 2017

Aritomo Tohda

8

1 reference

23 September 2017

Masahiro Fukuoka

9

1 reference

23 September 2017

Kazuhiko Nakagawa

10

1 reference

23 September 2017

publication date

1 March 2002

1 reference

23 September 2017

1 reference

23 September 2017

volume

35

1 reference

23 September 2017

issue

3

1 reference

23 September 2017

page(s)

299-304

1 reference

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900425-1

7 January 2021

Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900425-1

7 January 2021

Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900425-1

7 January 2021

Gene mutation analysis and quantitation of DNA topoisomerase I in previously untreated non-small cell lung carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900425-1

7 January 2021

No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900425-1

7 January 2021

Retroviral expression of a mutant (Gly-533) human DNA topoisomerase I cDNA confers a dominant form of camptothecin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900425-1

7 January 2021

Eukaryotic DNA topoisomerases I.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900425-1

7 January 2021

Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900425-1

7 January 2021

Higher expression of topoisomerase II in lung cancers than normal lung tissues: different expression pattern from topoisomerase I

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900425-1

7 January 2021

10.1016/S0169-5002(01)00425-1

Identifiers

DOI

1 reference

release_mqu3ql7p4bebnpsp5rbxospcpa

23 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mqu3ql7p4bebnpsp5rbxospcpa

24 November 2022

mapped directly with Wikidata item

1 reference